

## Maiden Profit

25 February 2026

Anagenics Limited (ASX:AN1, "Anagenics" or the "Company") is pleased to announce its financial results for the six months ended 31 December 2025 ('1H FY26').

### 1H FY26 Result Highlights

Following the Company's recent restructure, **Anagenics has retained 90% of Revenue vs the pcp while improving Gross Profit margin by 280bps**, and **reducing Operating Expenses by 44%**.

**The overall result is a material turnaround in earnings**, from a \$464k loss in 1H FY25 to a **maiden profit in 1H FY26 of \$127k**.

**Cash Flows continue to improve materially** vs the pcp following last year's restructure. The \$0.6m Operating Cash Outflow reported during 1H FY26 is a significant improvement from the \$1.2m Operating Cash Outflow reported in 1H FY25. Resolution of outstanding creditors drove negative Operating Cash Flow during 1H FY26, and it is expected this impact will end in 2H FY26.

Disposal of non-core business units such as the loss-making Face MediGroup has reduced Group overheads and complexity, contributing to annualised cost savings of \$2.5m. The Group also recently achieved an exit of 55 Clarence St via sublease, saving an additional ~\$100k in 2H FY26.

Over the past six months Anagenics has achieved a 20% reduction in liabilities, largely via a 43% improvement in creditor balances. With minimal change in the company's asset base, this has resulted in a **24% increase in Net Assets**.

**Anagenics also successfully completed a \$2.25m two-tranche equity raise**, with the first tranche (\$0.3m) completing in December 2025 and the second tranche (\$1.9m) completing in February 2026 after receiving shareholder approval. Funds received from the capital raising will be used to expand existing brands, pursue complementary value-accretive business opportunities, retire debt, working capital, and the costs of the placement.

**Key growth developments included the Company's agreement with Sydney-based York Street Brands** for access to Anagenics' hair regrowth technology and products, targeting a minimum \$4.4m over 10 years and currently runrating \$9m. This agreement delivered \$500k of royalties in 1H FY26.

**Management and the board remain focused on further building on these gains** in order to entrench long-term profitability for the benefit of our strategic partners and shareholders.

*This announcement was authorised by the Board of Anagenics Limited.*

**For further information, please contact:**

Sandy Beard  
Chair, Anagenics Limited  
P: 0412 308 263  
E: [sandy@xvgroup.com.au](mailto:sandy@xvgroup.com.au)

**Anagenics Limited (ASX:AN1)**

Anagenics is a health, beauty, and wellness business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products.

For further information, please see [www.anagenics.com](http://www.anagenics.com)